Oculis to Showcase Innovations at Upcoming Investor Conferences
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) is gearing up for significant investor conferences this November, wherein the company's management is excited to share updates on their innovative approaches in neuro-ophthalmology and ophthalmology.
Highlighting Breakthrough Developments
As the company transitions into a pivotal leader in eye care, Oculis is poised to unveil updates related to its late-stage product portfolio. The advancements primarily spotlight:
Privosegtor and the PIONEER Program
Oculis is thrilled to announce the advancement of Privosegtor within the PIONEER program, moving into registrational trials for conditions like acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION). This follows a highly positive engagement with the FDA, setting the stage for pivotal research.
OCS-01 in Diabetic Macular Edema Trials
Exciting topline results for the OCS-01 trials, aimed at treating diabetic macular edema, are anticipated by the second quarter of 2026. This ocular treatment could become a breakthrough in the management of this condition, impacting many lives positively.
Licaminlimab and Precision Medicine
Furthermore, Oculis is preparing to present data from the Licaminlimab trial, part of the PREDICT-1 program focused on dry eye disease (DED). This program is particularly exciting as it marks one of the first genotype-based initiatives aimed at delivering personalized treatment plans for patients.
Investor Conference Details
Oculis is set to feature prominently in several conferences this month:
Guggenheim Securities Healthcare Innovation Conference
Scheduled for November 10-12 in Boston, U.S., Oculis' CEO, Riad Sherif, M.D., will host a fireside chat on November 11 at 2:30 pm ET.
Stifel Healthcare Conference
Additionally, from November 11-13 in New York, Riad Sherif, M.D., will participate in a chat on November 12 at 2:00 pm ET, further discussing the company’s vision and progress.
LifeSci Capital and Sofinnova Partners Growth & Innovation Summit
On November 17 in London, Oculis management is anticipated to engage in one-on-one meetings to foster direct connections with potential investors.
ICR Healthcare Conference
Also on November 17 in London, Dr. Sherif will contribute to a panel discussion entitled ‘Brave New World,’ shedding light on transformative advancements in eye health.
Oculis will be accessible for individual meetings throughout these conferences, and potential investors are encouraged to reach out through their representatives for engagement opportunities.
About Oculis
Oculis is a pioneering biopharmaceutical firm focusing on neuro-ophthalmic conditions that require immediate attention and innovative solutions. Their late-stage clinical pipeline displays immense promise, featuring:
Core Product Candidates
Privosegtor: Targeting optic neuropathies, offering a fresh approach in the PIONEER program.
OCS-01: Aiming for first-line status in non-invasive treatment for diabetic macular edema.
Licaminlimab: A novel treatment under exploration with a strong emphasis on personalized medicine.
Headquartered in Switzerland with robust operations in the U.S. and Iceland, Oculis is backed by a seasoned management team whose mission resonates deeply: to improve eye health through breakthrough innovations.
Contact Information
Oculis Contact
Ms. Sylvia Cheung, CFO
Email: sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
Email: cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Email: oculis@icrhealthcare.com
Frequently Asked Questions
What is Oculis focused on?
Oculis specializes in developing innovative solutions for neuro-ophthalmology and ophthalmology, addressing unmet medical needs.
Who is the CEO of Oculis?
Dr. Riad Sherif serves as the CEO, leading the company's strategic initiatives and development programs.
When are the investor conferences taking place?
The conferences are scheduled for November 10-13 and November 17, across various locations in the U.S. and the U.K.
What key programs are being highlighted by Oculis?
Oculis highlights several key programs including Privosegtor, OCS-01, and Licaminlimab, each targeting significant ocular conditions.
How can investors engage with Oculis?
Investors can schedule one-on-one meetings with the Oculis management team during the conferences, reaching out through their representatives.